Lv61
1770 积分 2021-01-25 加入
Olverembatinib in chronic myeloid leukemia—Review of historical development, current status, and future research
2个月前
已完结
Considerations on the Dose and Schedule of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: Does Dose Matter?
3个月前
已关闭
Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia
4个月前
已完结
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial
4个月前
已完结
Final report of TKI discontinuation trial with dasatinib for the second attempt of treatment‐free remission after failing the first attempt with imatinib: Treatment‐free Remission Accomplished by Dasatinib (TRAD) study
4个月前
已完结
Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update
4个月前
已完结
Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial
4个月前
已完结
How to improve treatment‐free remission eligibility in chronic myeloid leukaemia?
4个月前
已完结
Patient‐reported outcomes in Chinese patients with chronic myeloid leukemia receiving olverembatinib: Quality of life matters!
5个月前
已完结
Risk of progression in chronic phase‐chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR‐PRO study
5个月前
已完结
皖公网安备34019202002308
